Arrowstreet Capital’s Protagonist Therapeutics PTGX Stock Holding History

Arrowstreet Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,076	Closed	-$443K	–	2052
2025 Q4	$443K	Buy	+5,076	New	+$415K	﹤0.01%	1701
2025 Q3	–	Sell	-17,856	Closed	-$987K	–	2071
2025 Q2	$987K	Buy	+17,856	New	+$857K	﹤0.01%	1616
2025 Q1	–	Sell	-216,069	Closed	-$8.34M	–	1970
2024 Q4	$8.34M	Buy	216,069 +58,002	+37%	+$2.53M	0.01%	872
2024 Q3	$7.11M	Buy	+158,067	New	+$6.39M	0.01%	859
2023 Q3	–	Sell	-14,895	Closed	-$411K	–	1388
2023 Q2	$411K	Buy	+14,895	New	+$373K	﹤0.01%	1084
2020 Q4	–	Sell	-66,928	Closed	-$1.31M	–	2487
2020 Q3	$1.31M	Sell	66,928 -17,489	-21%	-$328K	﹤0.01%	1736
2020 Q2	$1.49M	Buy	+84,417	New	+$1.06M	﹤0.01%	1602
2020 Q1	–	Sell	-20,000	Closed	-$141K	–	2067
2019 Q4	$141K	Buy	+20,000	New	+$199K	﹤0.01%	1645
2019 Q1	–	Sell	-28,602	Closed	-$192K	–	1872
2018 Q4	$192K	Sell	28,602 -63,439	-69%	-$503K	﹤0.01%	1256
2018 Q3	$947K	Buy	92,041 +8,700	+10%	+$74.9K	﹤0.01%	811
2018 Q2	$560K	Buy	+83,341	New	+$640K	﹤0.01%	899

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Arrowstreet Capital's PTGX Position: Q1 2026 in Review

Arrowstreet Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 5,076 shares — an estimated $443K sold.

Arrowstreet Capital first reported a position in PTGX in Q2 2018 and held it in 11 quarters. The position peaked at $8.34M in Q4 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Arrowstreet Capital reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
Arrowstreet Capital sold 5,076 Protagonist Therapeutics shares in Q1 2026, an estimated $443K.
Arrowstreet Capital first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 11 quarters.
Arrowstreet Capital's Protagonist Therapeutics position peaked at $8.34M in Q4 2024.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.